Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Dermatological Medicine
Volume 2018, Article ID 1680871, 5 pages
https://doi.org/10.1155/2018/1680871
Case Report

Topical Imiquimod for the Treatment of Relapsed Cutaneous Langerhans Cell Histiocytosis after Chemotherapy in an Elderly Patient

1Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
2Department of Internal Medicine, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
3Division of Plastic Surgery, Uji-Tokushukai Medical Center, Uji 611-0042, Japan
4Department of Pathology, Uji-Tokushukai Medical Center, Uji 611-0042, Japan

Correspondence should be addressed to Shinsaku Imashuku; pj.ro.teni-otoyk.xobm@59minihs

Received 12 August 2017; Revised 1 November 2017; Accepted 13 November 2017; Published 3 January 2018

Academic Editor: Ioannis D. Bassukas

Copyright © 2018 Shinsaku Imashuku et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. L. Berres, M. Merad, and C. E. Allen, “Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?” British Journal of Haematology, vol. 169, no. 1, pp. 3–13, 2015. View at Publisher · View at Google Scholar
  2. M. Aricò, M. Girschikofsky, T. Généreau et al., “Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society,” European Journal of Cancer, vol. 39, no. 16, pp. 2341–2348, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Minkov, N. Grois, A. Heitger, U. Potschger, T. Westermeier, and H. Gadner, “Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies,” Klinische Pädiatrie, vol. 212, no. 4, pp. 139–144, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Morimoto, Y. Shioda, T. Imamura et al., “Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study,” International Journal of Hematology, vol. 104, no. 1, pp. 99–109, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Park, C. Schiltz, and N. Korman, “Langerhans cell histiocytosis,” Journal of Cutaneous Medicine and Surgery, vol. 16, no. 1, pp. 45–49, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. L. M. Lindahl, M. Fenger-Grøn, and L. Iversen, “Topical nitrogen mustard therapy in patients with Langerhans cell histiocytosis,” British Journal of Dermatology, vol. 166, no. 3, pp. 642–645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. C. S. Sander, M. Kaatz, and P. Elsner, “Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide,” Dermatology, vol. 208, no. 2, pp. 149–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. A. E. Steen, K. H. Steen, R. Bauer, and T. Bieber, “Successful treatment of cutaneous Langerhans cell histiocytosis with low-dose methotrexate,” British Journal of Dermatology, vol. 145, no. 1, pp. 137–140, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. S. E. Chang, G. J. Koh, J. H. Choi et al., “Widespread skin-limited adult Langerhans cell histiocytosis: Long-term follow-up with good response to interferon alpha,” Clinical and Experimental Dermatology, vol. 27, no. 2, pp. 135–137, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Taverna, C. M. Stefanato, F. D. Wax, and M.-F. Demierre, “Adult cutaneous Langerhans cell histiocytosis responsive to topical imiquimod,” Journal of the American Academy of Dermatology, vol. 54, no. 5, pp. 911–913, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. D. O'Kane, H. Jenkinson, and J. Carson, “Langerhans cell histiocytosis associated with breast carcinoma successfully treated with topical imiquimod,” Clinical and Experimental Dermatology, vol. 34, no. 8, pp. e829–e832, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Aubert-Wastiaux, S. Barbarot, F. Mechinaud et al., “Childhood Langerhans cell histiocytosis associated with T cell acute lymphoblastic leukemia,” European Journal of Dermatology, vol. 21, no. 1, pp. 109-110, 2011. View at Google Scholar
  13. E. Dodd and K. Hook, “Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis,” Pediatric Dermatology, vol. 33, no. 3, pp. e184–e185, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Vidal, “Topical imiquimod: Mechanism of action and clinical applications,” Mini-Reviews in Medicinal Chemistry, vol. 6, no. 5, pp. 499–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. L. M. Imbertson, J. M. Beaurline, A. M. Couture et al., “Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463,” Journal of Investigative Dermatology, vol. 110, no. 5, pp. 734–739, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. J. R. Edelbroek, M. H. Vermeer, P. M. Jansen et al., “Langerhans cell histiocytosis first presenting in the skin in adults: Frequent association with a second haematological malignancy,” British Journal of Dermatology, vol. 167, no. 6, pp. 1287–1294, 2012. View at Publisher · View at Google Scholar · View at Scopus